News | April 25, 2024
Syngene International reports Q4 FY24 consolidated PAT at Rs. 188.6 Cr
Syngene International has reported total income of Rs. 933 crores during the period ended March 31, 2024
Syngene International has reported total income of Rs. 933 crores during the period ended March 31, 2024
New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day
For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)
Syngene has completed a payment of Rs. 158.2 crores on December 22, 2023 in addition to the initial payment of Rs. 395 crores made on December 1, 2023
The acquisition will add 20,000 litres of installed biologics drug substance manufacturing capacity for Syngene
Syngene gains access to ERS Genomics' foundational CRISPR/Cas9 patent portfolio, ushering in a new era of technical innovation in India for its global partners
Profit after tax (before exceptional items) up 23% to Rs 215 crores
Acquisition of biologics manufacturing facility in Bangalore to complete by the end of the third quarter in FY 24
Adding 20,000 liters of installed biologics drug substance manufacturing capacity
The company has posted net profit of Rs.464.4 crores for the Financial Year ended March 31, 2023
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)